221 related articles for article (PubMed ID: 33421278)
1. Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection.
Assini A; Gandoglia I; Damato V; Rikani K; Evoli A; Del Sette M
Eur J Neurol; 2021 Oct; 28(10):3537-3539. PubMed ID: 33421278
[TBL] [Abstract][Full Text] [Related]
2. New-onset Myasthenia Gravis after SARS-CoV-2 infection: case report and literature review.
Tereshko Y; Gigli GL; Pez S; De Pellegrin A; Valente M
J Neurol; 2023 Feb; 270(2):601-609. PubMed ID: 36352330
[TBL] [Abstract][Full Text] [Related]
3. [Anti-MuSK antibody positive myasthenia gravis with HIV infection successfully treated with cyclosporin: a case report].
Kurokawa T; Nishiyama T; Yamamoto R; Kishida H; Hakii Y; Kuroiwa Y
Rinsho Shinkeigaku; 2008 Sep; 48(9):666-9. PubMed ID: 19048951
[TBL] [Abstract][Full Text] [Related]
4. Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report.
Sakano S; Matsuyama H; Ishikawa H; Shindo A; Ii Y; Matsuura K; Mizutani M; Kawada N; Tomimoto H
BMC Neurol; 2020 Jun; 20(1):240. PubMed ID: 32532281
[TBL] [Abstract][Full Text] [Related]
5. Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.
Rivner MH; Pasnoor M; Dimachkie MM; Barohn RJ; Mei L
Neurol Clin; 2018 May; 36(2):293-310. PubMed ID: 29655451
[TBL] [Abstract][Full Text] [Related]
6. Spontaneously resolving late-onset ocular myasthenia related to COVID-19. A case report.
Popescu C
Acta Myol; 2023; 42(2-3):89-91. PubMed ID: 38090545
[TBL] [Abstract][Full Text] [Related]
7. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
[TBL] [Abstract][Full Text] [Related]
8. New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series.
Fanella G; Baiata C; Candeloro E; Toscano G; Colnaghi S; Mauri M; Cariddi LP; Rebecchi V; Solazzo F; Banfi P; Piatti M; Ferrarese C; Versino M
Neurol Sci; 2022 Oct; 43(10):5799-5802. PubMed ID: 35870026
[TBL] [Abstract][Full Text] [Related]
9. Anti-MuSK myasthenia gravis with prolonged remission.
Bouwyn JP; Magnier P; Bédat-Millet AL; Ahtoy P; Maltête D; Lefaucheur R
Neuromuscul Disord; 2016 Jul; 26(7):453-4. PubMed ID: 27161384
[TBL] [Abstract][Full Text] [Related]
10. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review.
Sriwastava S; Tandon M; Kataria S; Daimee M; Sultan S
J Neurol; 2021 Aug; 268(8):2690-2696. PubMed ID: 33047223
[TBL] [Abstract][Full Text] [Related]
11. MuSK Myasthenia Gravis Presenting with Bilateral Vocal Cord Abduction Paresis: A Case Report and Literature Review.
Santilli A; Stitt D
Neurologist; 2021 Sep; 26(5):175-177. PubMed ID: 34491934
[TBL] [Abstract][Full Text] [Related]
12. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
Vincent A; Leite MI
Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravis.
Peric S; Rankovic M; Bozovic I; Radosavljevic V; Marjanovic I; Basta I; Lavrnic D
Acta Neurol Belg; 2023 Apr; 123(2):529-536. PubMed ID: 36279094
[TBL] [Abstract][Full Text] [Related]
14. Temporal association between SARS-CoV-2 and new-onset myasthenia gravis: is it causal or coincidental?
Muralidhar Reddy Y; B SK; Osman S; Murthy JMK
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34290032
[TBL] [Abstract][Full Text] [Related]
15. Anti-MuSK myasthenia gravis presenting with purely ocular findings.
Caress JB; Hunt CH; Batish SD
Arch Neurol; 2005 Jun; 62(6):1002-3. PubMed ID: 15956173
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features of myasthenia related with autoantibodies to muscle specific tyrosine kinase (MuSK)].
Sanadze AG; Sidnev DV; Karganov MIu
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):72-6. PubMed ID: 21311492
[TBL] [Abstract][Full Text] [Related]
17. Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis.
Reddel SW; Morsch M; Phillips WD
Curr Opin Neurol; 2014 Oct; 27(5):558-65. PubMed ID: 25159928
[TBL] [Abstract][Full Text] [Related]
18. Myasthenia gravis patients with anti-MuSK antibodies.
Zagar M; Vranjes D; Sostarko M; Vogrinc Z; Bilić E; Trbojević Cepe M
Coll Antropol; 2009 Dec; 33(4):1151-4. PubMed ID: 20102061
[TBL] [Abstract][Full Text] [Related]
19. Cholinergic hyperactivity in patients with myasthenia gravis with MuSK antibodies: A neurophysiological study.
Modoni A; Mastrorosa A; Spagni G; Evoli A
Clin Neurophysiol; 2021 Aug; 132(8):1845-1849. PubMed ID: 34147009
[TBL] [Abstract][Full Text] [Related]
20. Comparison of three methods for the detection of antibodies against muscle-specific kinase.
Luong K; Lozier BK; Novis CL; Smith TL; Zuromski LM; Peterson LK
J Immunol Methods; 2024 Mar; 526():113627. PubMed ID: 38311009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
